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Abstract 
Objectives: National guidelines recommend prostate multiparametric (mp) MRI in men with suspected prostate 
cancer before biopsy. In this study, we explore prostate mpMRI protocols across 14 London hospitals and determine 
whether standardisation improves diagnostic quality.
Methods: An MRI physicist facilitated mpMRI set‑up across several regional hospitals, working together with expe‑
rienced uroradiologists who judged diagnostic quality. Radiologists from the 14 hospitals participated in the assess‑
ment and optimisation of prostate mpMRI image quality, assessed according to both PiRADSv2 recommendations 
and on the ability to “rule in” and/or “rule out” prostate cancer. Image quality and sequence parameters of representa‑
tive mpMRI scans were evaluated across 23 MR scanners. Optimisation visits were performed to improve image qual‑
ity, and 2 radiologists scored the image quality pre‑ and post‑optimisation.
Results: 20/23 mpMRI protocols, consisting of 111 sequences, were optimised by modifying their sequence parame‑
ters. Pre‑optimisation, only 15% of T2W images were non‑diagnostic, whereas 40% of ADC maps, 50% of high b‑value 
DWI and 41% of DCE‑MRI were considered non‑diagnostic. Post‑optimisation, the scores were increased with 80% of 
ADC maps, 74% of high b‑value DWI and 88% of DCE‑MRI to be partially or fully diagnostic. T2W sequences were not 
optimised, due to their higher baseline quality scores.
Conclusions: Targeted intervention at a regional level can improve the diagnostic quality of prostate mpMRI proto‑
cols, with implications for improving prostate cancer detection rates and targeted biopsies.
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Keypoints
• Standardisation of diagnostic image quality of pros-
tate multiparametric MRI is crucial to optimise clini-
cally significant prostate cancer detection.
• Pre-optimisation, the majority (85%) of the  T2 
-weighted images were partially or fully diagnos-
tic, whereas 40% of ADC maps, 50% of high b-value 
diffusion-weighted images and 41% of dynamic con-
trast-enhanced MRI were non-diagnostic.
• After applying the standardisation process across 
the several prostate multiparametric MRI protocols, 
the majority of the scores were increased resulting 
in 80% of ADC maps, 74% of high b-value diffusion-
weighted images and 88% of dynamic contrast-
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Introduction
Worldwide, there were an estimated 359,000 prostate 
cancer (PCa) deaths in 2018 [1]. The introduction of 
prostate multiparametric MRI (mpMRI) has revolution-
ised the management of PCa, improving diagnosis [2] 
and risk stratification of patients, and allowing appropri-
ate subsequent management [3, 4]. In 2019, the National 
Institute of Health and Care Excellence (NICE) updated 
prostate cancer guidelines endorsing the routine use of 
mpMRI in biopsy-naive men with suspected PCa [5].
A range of challenges are evident in implement-
ing prostate mpMRI nationally, many of which were 
discussed in the 2018 United Kingdom (UK) Prostate 
Cancer Consensus Meeting [6]. Several studies have 
highlighted that mpMRI quality varies substantially 
between centres and scanners, which is vulnerable to 
patient-related degradations, and that poor image quality 
is associated with greater uncertainty and lower accuracy 
[7–9]. Subsequently, the acquisition of mpMRI images of 
good diagnostic quality is crucial. Without this, any inter-
pretations made by radiologists (no matter how experi-
enced) is likely to be flawed and could subsequently lead 
to incorrect patient management.
Prostate mpMRI consists of 3 components: 
 T2-weighted (T2W) anatomical imaging, diffusion-
weighted MRI (DW-MRI) assessment of tissue cellular-
ity, and dynamic contrast-enhanced MRI (DCE-MRI) 
evaluation of tissue vascularity. Prostate Imaging and 
Reporting and Data System [10, 11] and UK Consensus 
meetings [6, 12, 13] have provided written guidance on 
imaging protocol set-up. However, there is currently no 
system in place whereby centres perform a formal qual-
ity check of their mpMRI scans to confirm diagnostic 
acceptability. Furthermore, smaller centres may have less 
experienced radiographers, generalist rather than spe-
cialist reporting radiologists and absence of MRI physi-
cist support, and therefore they are more likely to have 
non-optimised protocols.
This study explores regional prostate mpMRI protocols 
across 23 MR scanners situated across 14 London hospi-
tals by assessing their diagnostic quality and determining 
whether standardisation can improve their diagnostic 
quality.
Materials and method
An MRI physicist (M.-V.P.) experienced with prostate 
mpMRI (2  years) was employed by North Central and 
East London Cancer Alliance in a dedicated role to facili-
tate mpMRI set-up across the regional network hospitals. 
The physicist led the optimisation of mpMRI protocols 
over a year (from May 2018 to April 2019, based on the 
availability of time for optimisation at each hospital), 
working closely with 2 uroradiologists from the region 
leading hospital (C.A., L.D., each with > 5 years prostate 
mpMRI and reporting > 500 studies per year). In Fig.  1, 
the flow chart provides an outline of the optimisation 
process.
Optimisation set‑up
In June 2018, radiologists specialised in reporting pros-
tate mpMRI across different hospitals in North Central 
and East London Cancer Alliance network were invited to 
participate in a prostate imaging meeting. The aim of the 
meeting was to identify the need of acquiring acceptable 
diagnostic quality prostate mpMRI, to define an image 
quality system for prostate mpMRI and to invite them to 
participate in the set-up and use of a standardised and 
diagnostic quality protocol for prostate mpMRI. Subse-
quently, 20 radiologists from 14 hospitals (totally 23 MR 
scanners) participated (7 hospitals had 2 MR scanners 
and one had 3 scanners). These hospitals work indepen-
dently in terms of prostate mpMRI, but their relationship 
with the leading hospital is that all the prostate cancer 
surgery is performed at the leading hospital. Hence, it 
would be important all of them to adopt the same imag-
ing set-up ensuring high diagnostic quality of the pros-
tate mpMRI. Therefore, a quality assurance framework 
Fig. 1 Flow chart presenting the outline of the optimisation 
procedure of the prostate multiparametric (mp) MRI protocols
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for prostate mpMRI was proposed and accepted by the 
participants, aiming to establish a reliable imaging set-up 
and protocol across the region. The imaging set-up and 
protocol were determined following PiRADSv2 recom-
mendations which was current at the time the work com-
menced [10]. Based on PiRADSv2, required sequences 
for prostate mpMRI protocol were: (a) multiplanar T2W, 
(b) two DW-MRI sequences (one for the apparent diffu-
sion coefficient (ADC) map production and another for 
the high b-value diffusion-weighted imaging (DWI) and 
(c) one DCE-MRI sequence. The diagnostic image quality 
standards were defined based on the ability to “rule in” 
and “rule out” PCa [14]. According to recently proposed 
PI-QUAL scoring system [14], a 5-point scoring system 
was used for each required sequence, assigning: a) low 
score (1 or 2) as non-diagnostic, when it was not possi-
ble to either “rule in” or “rule out” PCa, b) medium score 
(3) as partially diagnostic, when it was possible to “rule 
in"  but not possible to “rule out” PCa, and c) a high score 
(4 or 5) as fully diagnostic, when it was possible to both 
“rule in” and “rule out” PCa.
Scanner characteristics, patient set-up and acquired 
sequences were recorded for each one of the protocols. 
A representative prostate mpMRI from each MR scan-
ner was assessed for sequence parameters by the physi-
cist compared to PiRADSv2 standards and for diagnostic 
quality by the two uroradiologists using the above 5-point 
scoring system.
Optimisation procedure
Following the review of MRI scans, visits for protocol 
optimisation were organised. The optimisation involved 
the modification of sequence parameters according to 
PiRADSv2 recommended sequence parameters and radi-
ologists’ scores. During the optimisation, images from 
the pre-optimised (original) protocol were acquired on 
real-life patients of each hospital list undergoing pros-
tate mpMRI, followed by optimised sequences (patients 
were consented for longer protocol duration). At the end 
of the optimisation session, an initial informal review of 
quality assessment was performed by at least two radi-
ologists, one from the leading and one or more from the 
visiting hospital, on the optimised sequences. Further 
visits were performed if the images were considered not 
yet fully optimised. Once completed, the new optimised 
protocol was integrated by the hospital. Due to the high 
baseline quality scores of T2W images, the DW-MRI and 
DCE-MRI protocols were prioritised for the optimisation 
process. For the DCE-MRI protocol optimisation, it was 
not possible to inject the patient twice. We acquired the 
pre-optimised sequence during contrast injection and 
the new sequence at time points just before and just after 
this in order to compare images with similar amounts of 
injected contrast in the tissue. When an improvement 
in the image quality was observed for the optimised 
sequence, that protocol was examined during the con-
trast agent injection and chosen as the final optimised.
Formal image review
The prostate MR images of PiRADSv2 required 
sequences were qualitatively assessed by two radiologists 
in consensus from the leading hospital, one with 20 years 
(C.A.) and another with 7  years (F.G.) reading experi-
ence. Five image acquisitions were reviewed: (1) axial 
T2W, (2) coronal T2W, (3) sagittal T2W, (4) ADC map, 
(5) high b-value DWI and (6) DCE-MRI. For the major-
ity of the scanners, DW-MRI and DCE-MRI sequences 
were acquired twice on the same patient, with the pre- 
and post-optimised sequences. The radiologists were 
unaware of which sequence was pre- and which was post-
optimisation. For each anonymised sequence, a qualita-
tive assessment was performed (Table 1) followed by an 
overall diagnostic acceptability using the pre-optimisa-
tion 5-point scoring system.
Results
From 23 prostate mpMRI protocols, one presented high 
diagnostic image quality and was used as an exemplar 
(Fig.  2). Two protocols were not optimised, because 
the optimisation visits could not be carried out. Sub-
sequently, 20 protocols were optimised, consisting of 
111 sequences, acquired by MRI scanners aged from 
1 to 16  years old (1/20 MRI scanner was 16  years old, 
3/20 were 14 years old, 4/20 were 9 years old, 5/20 were 
8  years old, 2/20 was 5  years old and 5/20 were 1  year 
old) from different manufacturers (7/20 S AG, Erlangen 
Germany, 7/20 GE Healthcare Waukesha, WI and 6/20 
Philips Healthcare, Best, The Netherlands); 4/20 operated 
at 3.0 T and 16/20 at 1.5 T.
Pre‑optimisation patient set‑up and imaging protocol
Patient set-up was evaluated in terms of patient position, 
coil and administration of antispasmodic agent. Only in 
1/20 (5%) protocol, patient’s position was headfirst. 15/20 
(75%) protocols utilised surface phased array coils and 
5/20 (25%) used body array coils. For 6/20 (30%), an anti-
spasmodic agent was administered prior to imaging.
2/20 (10%) protocols acquired only axial and coro-
nal T2W images, which was compliant with the newer 
PiRADSv2.1 recommendations, but not with the 
PiRADSv2. The other protocols acquired T2W across 
the 3 orthogonal orientations. 14/20 (70%) protocols 
acquired a high b-value DWI acquisition, where 2/14 
(14.3%) utilised the calculated high b-value DWI. 3/20 
(15%) protocols did not include DCE-MRI. The mean 
protocol duration was 33  min (range 18–45  min). For 
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all protocols, the sequence parameters of the reviewed 
sequences were evaluated against PiRADSv2 and 
PiRADSv2.1 standards (Table 2).
Post‑optimisation patient set‑up and imaging protocol
Only 1 sequence was optimised in 2/20 mpMRI proto-
cols, 2 sequences in 6/20, whereas 3 sequences in 12/20. 
In total, 50/57 (88%) sequences were either optimised or 
implemented including 18/20 (90%) sequences for ADC 
map production, 19/20 (95%) for high b-value DWI, and 
13/18 (72%) for DCE-MRI. The PiRADSv2 patient set-up 
was recommended, included feet first for patient’s com-
fort, surface coil and administration of an antispasmodic 
agent. 2/5 protocols adopted the cardiac coil and 5/14 
protocols the administration of an antispasmodic agent. 
3/20 (15%) hospitals did not have a cardiac or surface 
coil. 3/20 (15%) protocols included the high b-value DWI 
with a 5 min increase in protocol duration and 1/3 proto-
col included DCE-MRI. The mean protocol duration fol-
lowing optimisation was 33 min (range 21–43 min).
All DW-MRI sequences used the same b-values for the 
ADC map, the spatial resolution and FOV all complied 
with PiRADSv2 but with a 5 mm slice thickness. For the 
high b-value DWI, all the 1.5 T sequences encompassed 
the b-value of 1400  s/mm2 and all the 3.0  T protocols 
a b-value of 2000  s/mm2 and thus were compliant with 
PiRADSv2. In DCE, the slice thickness, the spatial resolu-
tion adhered to PiRADSv2, the temporal resolution was 
longer but then adhered to PiRADSv2.1.
Overall diagnostic acceptability per imaging protocol
In 13/20 mpMRI protocols, both DW-MRI and DCE-
MRI sequences were completely optimised and complied 
with PiRADSv2, whereas in 7/20 protocols it was not 
possible for all sequences to be fully optimised (Fig.  2). 
The scores per sequence pre- and post-optimisation for 
the completely and incompletely optimised protocols are 
presented in Figs. 3, 4 and 5.
After the optimisation, the number of fully and par-
tially diagnostic sequences was increased. Post-optimi-
sation, 9/39 (23%) DW-MRI sequences were scored as 
Table 1 Diagnostic quality assessment questionnaire
T2‑Weighted Diffusion‑weighted imaging (DWI) Dynamic contrast‑
enhanced MRI
Axial Coronal Sagittal DWI High b‑value DWI
Angulation Yes/no Yes/no Yes/no Yes/no Yes/no Yes/no
Does the current 
angulation match 




































b‑values (s/mm2) 0, 150, 500, 1000 1400 @ 1.5 T
 2000 @ 3.0 T
Artifacts Yes/no Yes/no Yes/no Yes/no Yes/no Yes/no
Image blurring due 
to motion
Yes/no Yes/no Yes/no Yes/no Yes/no Yes/no
Is it possible to rule 
in tumours?
Yes/no Yes/no Yes/no Yes/no Yes/no Yes/no
Is it possible to rule 
out tumours?
Yes/no Yes/no Yes/no Yes/no Yes/no Yes/no










of each dynamic 
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non-diagnostic. In all of these cases, the age (> 8  years 
old) of the MR scanners restricted the optimisation pro-
cess and necessitated longer protocol durations for full 
implementation of PiRADSv2 recommendations. The 
corresponding hospitals were unable to accommodate 
any further increase in protocol duration due to schedul-
ing constraints.
Image quality of T2‑weighted images
For the majority of the protocols, the T2W sequences 
were partially or fully diagnostic (Fig.  3). For the axial 
T2W sequences, 3/20 (15%) sequences were non-
diagnostic, 5/20 (25%) were partially, and 12/20 (60%) 
were fully diagnostic. For the coronal T2W, 3/20 (15%) 
sequences were non-diagnostic, 6/20 (30%) were par-
tially, and 11/20 (55%) were fully diagnostic. For the 
sagittal T2W, 3/18 (16.7%) sequences were non-diag-
nostic, 7/18 (38.9%) were partially, and 8/18 (40%) 
were fully diagnostic. Non-diagnostic T2W sequences 
were associated with poor image resolution and low 
signal-to-noise ratio (SNR) (acquired pixel size of 0.8 
to 1.5  mm across the frequency encoding (FE) and 
the phase encoding (PE) direction). Good image reso-
lution was associated with an acquired pixel size of 
0.7 mm across the FE and PE directions. Optimisation 
of the T2W sequences on early hospital visits made no 
measurable difference to quality scores (in 6/20 (30%) 
scanners), and due to time constraints, priority was 
subsequently given to DWI and DCE on further visits.
Fig. 2 Flow chart presenting the initial number of assessed prostate multiparametric (mp) MRI protocols and the final number completely 
optimised acquiring all the recommended sequences. (DWI: diffusion‑weighted imaging, DCE: dynamic contrast enhanced)
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Image quality of apparent diffusion coefficient (ADC) maps
Pre-optimisation, the scores of the ADC maps (Figs. 4a, 
5a) showed that 8/20 (40%) sequences were non-diag-
nostic, 7/20 (35%) were partially, and 5/20 (25%) were 
fully diagnostic. Non-diagnostic ADC maps were asso-
ciated with large FOVs (ranged from 250 to 380  mm) 
(Fig.  6a), poor image resolution (acquired pixel size 
ranged from 2.6 mm to 4.8 mm across FE and PE direc-
tions) and low SNR (slice thickness smaller than 5 mm, 
with less than 3 b-values in combination with the num-
ber of signal averages (NSA)).
Table 2 Summary of acquisition parameters range prior the optimisation related to Prostate Imaging Reporting and Data System 
(PiRADSv2 and v2.1)
Sequence parameter PiRADSv2 standard (PiRADSv2.1 standard) Mean Range
Axial T2-weighted
Field of view (mm) 120–200 200 170–240
Slice thickness (mm) 3 3.2 3–4
Slice gap (mm) 0 0.3 0.‑0.75
Acquired pixel size (mm) × (mm) ≤ 0.4 (frequency) 0.7 (frequency) 0.5–1.0
≤ 0.7 (phase) 0.9 (phase) 0.6–1.3
Coronal T2-weighted
Field of view (mm) 120–200 204 180–240
Slice thickness (mm) 3 3.1 3–4
Slice gap (mm) 0 0.3 0–0.7
Acquired pixel size (mm) × (mm) ≤ 0.4 (frequency) 0.7 (frequency) 0.5–1.0
≤ 0.7 (phase) 0.9 (phase) 0.6–1.1
Sagittal T2-weighted
Field of view (mm) 120–200 212 180–250
Slice thickness (mm) 3 3.5 3–6
Slice gap (mm) 0 0.4 0–2
Acquired pixel size (mm) × (mm) ≤ 0.4 (frequency) 0.8 (frequency) 0.6–1.1
≤ 0.7 (phase) 1.0 (phase) 0.6–1.5
Diffusion-weighted MRI (DW-MRI)
Repetition time (ms) ≥ 3000 4921 1320 ‑23,651
Echo time (ms) ≤ 90 80 48–117
Field of view (mm) 160–220 275 220–380
Slice thickness (mm) ≤ 4 4.45 2.5–6
Slice gap (mm) 0 0.5 0–1
Acquired pixel size (mm) × (mm) ≤ 2.5 (frequency) 2.23 1.3–4.8
≤ 2.5 (phase) 2.64 1.5–4.8
Number of b‑values for ADC map At least 2 b‑values 3.35 2–4
Proposed b‑values (s/mm2) (0), 50, 150, 500, 1000
High b‑value (s/mm2) 1400 at 1.5 T 1333 1200–1500
2000 at 3 T 1400 1200–1600
Dynamic contrast-enhanced MRI (DCE-MRI)
Repetition time (ms) < 100 5.4 3.2–8.2
Echo time (ms) < 5 2.25 1.6–3.2
Field of view (mm) Encompass the entire prostate gland and the 
seminal vesicles
274 205–400
Slice thickness (mm) 3 3 2–6
Slice gap (mm) 0 0.8 0–3
Acquired pixel size (mm) × (mm) ≤ 2.0 (frequency) 1.4 0.75–1.65
≤ 2.0 (phase) 1.5 0.75–2.07
Temporal resolution (s) ≤ 10 ( ≤ 15) 14.7 6–32
Total duration ≥ 2 min 5 min 2 min–10 min 46 sec
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Post-optimisation, 18/20 (90%) sequences were modi-
fied, resulting in improvement from 4/18 (22.2%) to 
7/18 (38.9%) fully diagnostic, from 6/18 (33.3%) to 7/18 
(38.9%) partially diagnostic and a reduction from 8/18 
(44.4%) to 4/18 (22.2%) non-diagnostic ADC maps. 
For some MR scanners, longer protocol duration was 
required for improved diagnostic quality. For example: 
for the SNR increase, the number of signal averages 
(NSA) had to be increased resulting in a longer protocol 
duration; for image resolution improvement, the voxel 
size had to be reduced by increasing the number of phase 
encoding lines in the acquisition matrix, which increased 
further the protocol duration. However, these hospitals 
were unable to increase their protocol duration despite 









Fig. 3 Scores of the image quality assessment of the  T2‑weighted (T2W) (axial, coronal and sagittal) images. The numbers denote the MR scanners



























Fig. 4 Pre‑ and post‑optimisation scores of the completely optimised multiparametric MRI protocols of (a) apparent diffusion coefficient (ADC) 
maps, (b) high b‑value diffusion‑weighted (DW) images and (c) dynamic contrast‑enhanced (DCE) MRI. The numbers denote the MR scanners
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the suggestions; subsequently, some ADC maps remained 
non-diagnostic after the optimisation. Figure  6d shows 
an example of an ADC map with optimal FOV post-opti-
misation, as compared with the pre-optimisation large 
FOV acquired from the same patient (Fig. 6a).
Image quality of high b‑value diffusion‑weighted images
Pre-optimisation, 16/20 protocols included the acquisi-
tion or the calculation of the separate high b-value DWI 
(Figs. 4b, 5b). 8/16 (50%) sequences were non-diagnostic, 
7/16 (43.8%) were partially, and 1/16 (6.2%) was fully 
diagnostic. Non-diagnostic high b-value DWI was asso-
ciated with large FOV, poor image resolution and low 
SNR. The range of the large FOV and the acquired pixel 
size resulting in poor image resolution was the same as 
the ADC maps (Fig. 6b). Low SNR was reported for slice 
thickness smaller than 5 mm with few NSA, ranged from 
2 to 8, and small acquired pixel size, ranged from 1.3 mm 
to 2.5 mm.
Post-optimisation, 16/20 (75%) high b-value DW 
sequences were optimised and another 3 were 
implemented, resulting in improvement from 1/16 (6.2%) 
to 9/19 (47.7%) fully diagnostic, a reduction from 7/16 
(43.8) to 5/19 (26.3%) partially diagnostic and from 8/16 
(50%) to 5/19 (26.3%) non-diagnostic high b-value DWI. 
An example of an optimised high b-value DW image is 
presented in Fig. 6e, where an optimal FOV without chem-
ical shift artefact is illustrated post-optimisation, as com-
pared to the large FOV with the chemical shift artifact on 
pre-optimisation image for the same patient (Fig. 6b).
Image quality of dynamic contrast‑enhanced MRI
17/20 (85%) prostate mpMRI protocols included DCE-
MRI (Figs.  4c, 5c). 7/17 (41.1%) DCE-MRI sequences 
were non-diagnostic, 5/17 (29.4%) were partially and 5/17 
(29.4%) fully diagnostic. The non-diagnostic sequences 
were associated with poor image resolution, (resulted 
by a thick slice ( ≥3  mm) or a large acquired pixel size 
ranged from 1.48 to 2.02 mm), large FOV (ranged from 
260 to 400 mm) and low SNR (depicted to acquired pixel 
size, ranged from 0.88 to 1.65 mm or to a slice < 3 mm). 



























Fig. 5 Pre‑ and post‑optimisation scores of the incompletely optimised multiparametric MRI protocols of (a) apparent diffusion coefficient (ADC) 
maps, (b) high b‑value diffusion‑weighted (DW) images and (c) dynamic contrast‑enhanced (DCE) MRI. The numbers denote the MR scanners
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Figure 6c presents a poor image quality DCE acquisition 
without a fat suppression technique.
12/20 (60%) DCE sequences were optimised and one 
new sequence was implemented. Post-optimisation, the 
scores were improved from 3/12 (25%) to 6/13 (46.1%) 
fully diagnostic, from 3/12 (25%) to 6/13 (46.1%) par-
tially diagnostic and a reduction from 6/12 (50%) to 
1/13 (7.7%) non-diagnostic DCE-MRI. Figure  6f pre-
sents a DCE image post-optimisation with fat suppres-
sion technique of the 3rd post-contrast measurement, as 
compared to the pre-optimisation image without fat sup-
pression for the same patient (Fig. 6c).
Discussion
In the current study, prostate mpMRI protocols across 23 
MR scanners situated across 14 London hospitals were 
explored, and after standardisation, the overall diagnostic 
quality was improved in the majority. The initial protocol 
heterogeneity, in terms of patient set-up, sequence type and 
parameters, was reduced after the optimisation resulting 
in a common and standardised procedure. Post-optimisa-
tion, the diagnostic acceptability of mpMRI was improved, 
increasing radiologists’ confidence in “ruling in” and “ruling 
out” PCa. Other multicentre studies highlighted the need 
for prostate mpMRI optimisation not only to comply with 
PiRADSv2 [7, 15], but also to produce scans with adequate 
diagnostic quality [9]. Jorge et al. [16] introduced the role 
of director of imaging for standardising prostate mpMRI 
performance. Five mpMRI protocols of 4 institutions were 
assessed and modified only according to PiRADSv2 stand-
ards, without examining their diagnostic image quality. To 
our knowledge, there is no other study assessing and opti-
mising mpMRI protocols across different hospitals accord-
ing to PiRADSv2 standards and their diagnostic image 
quality pre- and post-optimisation.
PiRADSv2 standards were used for study design 
and optimisation. These standards were updated to 
PiRADSv2.1 during the course of the study. For example, 
although 3 orthogonal planes were required for PIRADSv2 
for the T2W images, PiRADSv2.1 only requires axial and 
Fig. 6 Images (a–c) acquired pre‑optimisation, showing: a apparent diffusion coefficient (ADC) map with large field of view; b high b‑value 
diffusion‑weighted (DW) image with large field of view and chemical shift artefact; c dynamic contrast‑enhanced (DCE) image without fat 
suppression technique, 30th measurement post‑contrast. Following optimisation, images (d–f) demonstrated the changes in the image quality 
at the same patient: d ADC map with optimal field of view; e high b‑value diffusion‑weighted (DW) image with optimal field of view and without 
chemical shift artefact; f DCE image with fat suppression technique, 3rd measurement post‑contrast
Page 10 of 11Papoutsaki et al. Insights Imaging           (2021) 12:52 
one additional plane. In general, PiRADSv2.1 criteria were 
less restrictive than PiRADSv2. However, it should be men-
tioned that compliance with PiRADS guidelines does not 
necessarily equate to good image quality [8], for some scan-
ners maintaining technical compliance reduced diagnos-
tic quality. It should be mentioned that we included in the 
optimisation the DCE-MRI, despite the fact that its inclu-
sion is controversial in prostate mpMRI. Currently there is 
not enough evidence to confirm its exclusion.
This study aimed at improving image quality using the 
existing scanner resources at each of the 14 hospitals. 
Post-optimisation, the practice at 5/14 (36%) hospitals was 
changed to include the use of antispasmodics and 1/3 hos-
pital added a DCE protocol. The diagnostic acceptability 
was improved. 14% sequences for the ADC map production 
became fully diagnostic (totally 40%), 40% were partially 
diagnostic and 20% non-diagnostic. Regarding the high 
b-value DWI, 41.2% became fully diagnostic (totally 47.4%) 
and 26.3% remained partially and 26.3% non-diagnostic. 
17% DCE-MRI became fully diagnostic (totally 47%), 41% 
were partially and 12% non-diagnostic. These results depict 
the various challenges during the optimisation.
The major challenge was to perform the optimisation 
in men undergoing prostate mpMRI within the routine 
schedule of each hospital. This was achieved by adding 
10 min to each prostate mpMRI scan, enabling the acqui-
sition of pre- and post-optimised sequences for each 
patient. Several iterations of post-optimised sequences 
were required in order to achieve best quality images, 
best achieved over several different scans in order that 
the length of scan for each patient was not excessive. 
This approach required the booking of at least 4 prostate 
mpMRI scans during  each optimisation  session, although 
this was difficult to schedule for the majority of the hospi-
tals. For at least one of the booked scans, either the patient 
did not attend the session or had MR contraindications or 
was unable to tolerate the scan any longer. In some cases, 
the anatomical factors (e.g. after radical prostatectomy) did 
not allow the optimisation to be carried out. Other "real-
life" limitations included the presence of rectal air, deterio-
rating the optimisation in DW-MRI sequences, especially 
where no antispasmodic agent was administered [17]. It is 
known that the different magnetic susceptibilities of pros-
tate tissue and rectal air introduce magnetic field inhomo-
geneities which can result in distortions or in signal voids 
at the posterior part of prostate [18].
Another limiting factor was in the different capabilities 
of the MR scanners, which varied in field strength, manu-
facturer, age, hardware and software. For old (age > 8 years) 
3.0 T scanners, the optimisation of the DW-MRI sequences 
was more challenging, as compared to the new (1  year) 
3.0 T scanners. In patients’ scans where no antispasmodic 
agent was administered and the rectum was full of air, 
distortions and signal voids were more prominent at 3.0 T 
due to the magnetic field inhomogeneities, as compared to 
the 1.5 T scanners. At high b-value DW-MRI at 3.0 T, the 
suggested b-value (b = 2000  s/mm2) required higher NSA 
to increase SNR and image quality [6, 10]. However, this 
as well as the increase of spatial resolution and SNR led to 
a longer acquisition time, which was not possible in some 
hospitals in terms of workload capacity, resulting in non-
diagnostic sequences post-optimisation (scanners 8 and 16). 
These hospitals mentioned that a longer protocol duration 
would have an impact on their clinical scheduling. Either 
the radiographers would work out of hours or less patients 
would be scanned daily. At 1.5  T scanners, the age and 
the different software also influenced the optimisation. In 
older scanners (scanners 2, 11 and 19), the recommended 
reduced FOV in combination with an adequate image res-
olution in DW-MRI resulted in a remarkable reduction in 
SNR, although this could not be justified by the significant 
increase in acquisition time. Indeed, time constraints were 
a major restriction on sequence optimisation due to sched-
uling constraints typical of busy imaging services. For the 
majority of the hospitals, three to four visits were needed for 
a completed optimisation for all the sequences. However, it 
was not feasible for many hospitals to accommodate more 
than one visit in their daily clinical schedule. Ideally, optimi-
sation should be considered an ongoing process, and with 
planned scanner updates, upfront optimisation will further 
improve network standards and diagnostic quality. Lastly, 
the majority of the hospitals did not include the use of any 
antispasmodic agent initially. However, during the course 
of the optimisation, some hospitals used an antispasmodic 
agent as a test. The radiologists of these observed the posi-
tive impact on the image quality of this agent; subsequently, 
they decided to adopt it in their clinical practice.
Our study has some limitations. The optimised sequences 
could only be acquired and scored only in one patient; sub-
sequently, we recognised that the image quality assessment 
was also dependant on patient’s body habitat. Ideally scans 
should be acquired on many more patients and scored 
both pre- and post-optimisation. Moreover, the pre- and 
post-optimised DCE-MRI sequences were acquired and 
compared either pre- or post-injection, because it was not 
feasible to inject the same patient twice. For few protocols, 
the DCE-MRI was not optimised, and this was due to lim-
ited time for optimisation at the particular hospitals. Lastly, 
the overall impact of the optimisation on diagnosis and 
management was not assessed, due to the fact that it was 
beyond the study scope and duration.
This study explored regional prostate mpMRI protocols 
across 23 MR scanners situated across 14 London hos-
pitals, demonstrated heterogeneity in diagnostic qual-
ity and showed how targeted intervention could help 
standardise and improve diagnostic quality. We show a 
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methodology for engagement of non-specialist hospitals, 
show which scans typically are problematic and quan-
tify how much of a change this type of intervention can 
achieve. Although populations and the management of 
healthcare differs by region, the information presented 
should be informative for many settings. This work pre-
sents as an example the prostate mpMRI standardisation 
across a hospital network in London. Other hospitals or 
countries might adopt a different approach depending on 
their regulations and their clinical schedule.
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